Sale

Neuroendocrine Tumours Treatment Market

Global Neuroendocrine Tumours Treatment Market Share, Size: By Treatment Type: Targeted Therapy, Chemotherapy, Somatostatin Analogues (SSAs); By Indication: Gastrointestinal NET, Lung NET, Others; By End-Use; Regional Analysis; Competitive Landscape; Key Trends and Developments in the Market; 2024-2032

Global Neuroendocrine Tumours Treatment Market Outlook

The global neuroendocrine tumours treatment market would likely grow at a CAGR of 10.1% during 2024-2032. The number of patients with neuroendocrine tumours is increasing (generally with metastatic disease, and warranting systemic therapy) across the globe. Asia, North America and Europe are likely to be key markets. 

 

neuroendocrine tumours treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Growth Likely to be Driven by Increasing Occurrence of Neuroendocrine Tumours Across the Globe

Neuroendocrine tumours refer to rare tumours that may occur in several different organs of the body. Symptoms of neuroendocrine tumours largely depend on tumours’ location in the body and the hormones these produce. As an example, a gastrointestinal neuroendocrine tumour may lead to symptoms such as diarrhoea, constipation or stomach aches; pulmonary neuroendocrine tumours may give birth to wheezing or incessant cough; some tumours may cause the release of very large amounts of hormones into the bloodstream. Such tumours are called "functioning tumours" and may lead to symptoms including flushing, diarrhoea, wheezing, cramps, hypoglycaemia, changes in blood pressure, and heart problems.

 

Procedures and tests carried out to diagnose a neuroendocrine tumour may include  a physical examination (including looking for swollen lymph nodes or indications that a tumour is releasing excess hormones), tests to identify release of excess hormones (including urine or blood tests to identify excess hormones generated by  neuroendocrine tumours), imaging tests [including MRI, CT, ultrasound, to generate  images of the tumour; for neuroendocrine tumours, positron emission tomography (PET) may be employed), and biopsy. Additional tests may be carried out if there is a risk that the neuroendocrine tumour may have spread to other parts of the body.

 

Treatment for neuroendocrine tumour depends on the type and location of tumour, and the symptoms and excess hormones released by the tumour. Treatment options include chemotherapy, surgery, peptide receptor radionuclide therapy (PRRT), targeted drug therapy, radiation therapy, and medications to regulate excess hormones.   

 

Innovations in Treatment Systems Likely to Boost Market Growth

Leading companies are engaged in developing innovative solutions for the treatment of neuroendocrine tumours. For example, in 2018, Novartis AG announced that new drug application (NDA) of Advanced Accelerator Applications (a subsidiary of Novartis Groupe S.A.) obtained US FDA approval for Lutathera® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including midgut, foregut, and hindgut neuroendocrine tumors, in adults. Lutathera, was a first-in-class drug (a drug employing a novel and unique mechanism of action to treat a medical condition) and the first available FDA-approved Peptide Receptor Radionuclide Therapy (PRRT). Such developments are likely to boost the global neuroendocrine tumours treatment market.

 

Market Segmentation

 

neuroendocrine tumours treatment market by segmentation

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

By treatment type, the market is segmented into:

  • Targeted Therapy
  • Chemotherapy
  • Somatostatin Analogues (SSAs)

 

By indication, the market is divided into:

  • Gastrointestinal NET
  • Lung NET
  • Pancreatic NET
  • Others

 

By end use, the market is divided into:

  • Hospitals
  • Clinics
  • Others

 

By region, the market is segmented into:

  • Europe
  • North America
  • Latin America
  • Asia Pacific
  • Middle East and Africa

 

neuroendocrine tumours treatment market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Key Industry Players in the Market

The report offers an extensive assessment of major players in the global neuroendocrine tumours treatment market; it evaluates their capability, observes latest occurrences such as mergers and acquisitions, capacity expansions, and plant turnarounds:

 

  • Pfizer Inc
  • Novartis AG
  • Ipsen Pharma
  • Abbvie Inc.
  • AVEO Pharmaceuticals, Inc
  • Others

 

Using SWOT analysis and Porter’s Five Forces model, the EMR report offers deep insights into the industry.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Treatment Type
  • Indication
  • End-Use
  • Region
Breakup by Treatment Type
  • Targeted Therapy
  • Chemotherapy
  • Somatostatin Analogues (SSAs)
Breakup by Indication
  • Gastrointestinal NET
  • Lung NET
  • Pancreatic NET
  • Others
Breakup by End-Use
  • Hospitals
  • Clinics
  • Others
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Pfizer Inc
  • Novartis AG
  • Ipsen Pharma
  • Abbvie Inc.
  • AVEO Pharmaceuticals, Inc
  • Others

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties 
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Neuroendocrine Tumors Treatment Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Neuroendocrine Tumours Treatment Historical Market (2017-2023) 
    8.3    Global Neuroendocrine Tumours Treatment Market Forecast (2024-2032)
    8.4    Global Neuroendocrine Tumours Treatment Market by Treatment Type
        8.4.1    Targeted Therapy
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2017-2023)
            8.4.1.3    Forecast Trend (2024-2032)
        8.4.2    Chemotherapy
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2017-2023)
            8.4.2.3    Forecast Trend (2024-2032)
        8.4.3    Somatostatin Analogues (SSAs)
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2017-2023)
            8.4.3.3    Forecast Trend (2024-2032)
    8.5    Global Neuroendocrine Tumours Treatment Market by Indication
        8.5.1    Gastrointestinal NET
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2017-2023)
            8.5.1.3    Forecast Trend (2024-2032)
        8.5.2    Lung NET
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2017-2023)
            8.5.2.3    Forecast Trend (2024-2032)
        8.5.3    Pancreatic NET
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2017-2023)
            8.5.3.3    Forecast Trend (2024-2032)
        8.5.4    Others
    8.6    Global Neuroendocrine Tumours Treatment Market by End-Use
        8.6.1    Hospitals
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2017-2023)
            8.6.1.3    Forecast Trend (2024-2032)
        8.6.2    Clinics
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2017-2023)
            8.6.2.3    Forecast Trend (2024-2032)
        8.6.3    Others
    8.7    Global Neuroendocrine Tumours Treatment Market by Region
        8.7.1    North America
            8.7.1.1    Market Share
            8.7.1.2    Historical Trend (2017-2023) 
            8.7.1.3    Forecast Trend (2024-2032)
        8.7.2    Europe
            8.7.2.1    Market Share
            8.7.2.2    Historical Trend (2017-2023) 
            8.7.2.3    Forecast Trend (2024-2032)
        8.7.3    Asia Pacific
            8.7.3.1    Market Share
            8.7.3.2    Historical Trend (2017-2023) 
            8.7.3.3    Forecast Trend (2024-2032)
        8.7.4    Latin America
            8.7.4.1    Market Share
            8.7.4.2    Historical Trend (2017-2023) 
            8.7.4.3    Forecast Trend (2024-2032)
        8.7.5    Middle East and Africa
            8.7.5.1    Market Share
            8.7.5.2    Historical Trend (2017-2023) 
            8.7.5.3    Forecast Trend (2024-2032)
9    North America Neuroendocrine Tumours Treatment Market Analysis
    9.1    United States of America 
        9.1.1    Market Share
        9.1.2    Historical Trend (2017-2023) 
        9.1.3    Forecast Trend (2024-2032)
    9.2    Canada
        9.2.1    Market Share
        9.2.2    Historical Trend (2017-2023) 
        9.2.3    Forecast Trend (2024-2032)
10    Europe Neuroendocrine Tumours Treatment Market Analysis
    10.1    United Kingdom
        10.1.1    Market Share
        10.1.2    Historical Trend (2017-2023) 
        10.1.3    Forecast Trend (2024-2032)
    10.2    Germany
        10.2.1    Market Share
        10.2.2    Historical Trend (2017-2023) 
        10.2.3    Forecast Trend (2024-2032)
    10.3    France
        10.3.1    Market Share
        10.3.2    Historical Trend (2017-2023) 
        10.3.3    Forecast Trend (2024-2032)
    10.4    Italy
        10.4.1    Market Share
        10.4.2    Historical Trend (2017-2023) 
        10.4.3    Forecast Trend (2024-2032)
    10.5    Others
11    Asia Pacific Neuroendocrine Tumours Treatment Market Analysis
    11.1    China
        11.1.1    Market Share
        11.1.2    Historical Trend (2017-2023) 
        11.1.3    Forecast Trend (2024-2032)
    11.2    Japan
        11.2.1    Market Share
        11.2.2    Historical Trend (2017-2023) 
        11.2.3    Forecast Trend (2024-2032)
    11.3    India
        11.3.1    Market Share
        11.3.2    Historical Trend (2017-2023) 
        11.3.3    Forecast Trend (2024-2032)
    11.4    ASEAN
        11.4.1    Market Share
        11.4.2    Historical Trend (2017-2023) 
        11.4.3    Forecast Trend (2024-2032)
    11.5    Australia
        11.5.1    Market Share
        11.5.2    Historical Trend (2017-2023) 
        11.5.3    Forecast Trend (2024-2032)
    11.6    Others
12    Latin America Neuroendocrine Tumours Treatment Market Analysis
    12.1    Brazil
        12.1.1    Market Share
        12.1.2    Historical Trend (2017-2023) 
        12.1.3    Forecast Trend (2024-2032)
    12.2    Argentina
        12.2.1    Market Share
        12.2.2    Historical Trend (2017-2023) 
        12.2.3    Forecast Trend (2024-2032)
    12.3    Mexico
        12.3.1    Market Share
        12.3.2    Historical Trend (2017-2023) 
        12.3.3    Forecast Trend (2024-2032)
    12.4    Others
13    Middle East and Africa Neuroendocrine Tumours Treatment Market Analysis
    13.1    Saudi Arabia
        13.1.1    Market Share
        13.1.2    Historical Trend (2017-2023) 
        13.1.3    Forecast Trend (2024-2032)
    13.2    United Arab Emirates
        13.2.1    Market Share
        13.2.2    Historical Trend (2017-2023) 
        13.2.3    Forecast Trend (2024-2032)
    13.3    Nigeria
        13.3.1    Market Share
        13.3.2    Historical Trend (2017-2023) 
        13.3.3    Forecast Trend (2024-2032)
    13.4    South Africa
        13.4.1    Market Share
        13.4.2    Historical Trend (2017-2023) 
        13.4.3    Forecast Trend (2024-2032)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
15    Competitive Landscape
    15.1    Market Structure
    15.2    Company Profiles
        15.2.1    Pfizer Inc
            15.2.1.1    Company Overview
            15.2.1.2    Product Portfolio
            15.2.1.3    Demographic Reach and Achievements
            15.2.1.4    Certifications
        15.2.2    Novartis AG
            15.2.2.1    Company Overview
            15.2.2.2    Product Portfolio
            15.2.2.3    Demographic Reach and Achievements
            15.2.2.4    Certifications
        15.2.3    Ipsen Pharma
            15.2.3.1    Company Overview
            15.2.3.2    Product Portfolio
            15.2.3.3    Demographic Reach and Achievements
            15.2.3.4    Certifications
        15.2.4    Abbvie Inc.
            15.2.4.1    Company Overview
            15.2.4.2    Product Portfolio
            15.2.4.3    Demographic Reach and Achievements
            15.2.4.4    Certifications
        15.2.5    AVEO Pharmaceuticals, Inc
            15.2.5.1    Company Overview
            15.2.5.2    Product Portfolio
            15.2.5.3    Demographic Reach and Achievements
            15.2.5.4    Certifications
        15.2.6    Others
16    Key Trends and Developments in the Market

 

List of Figures and Tables

1.    Global Neuroendocrine Tumours Treatment Market: Key Industry Highlights, 2017 and 2032
2.    Global Neuroendocrine Tumours Treatment Historical Market: Breakup by Treatment Type (USD Million), 2017-2023
3.    Global Neuroendocrine Tumours Treatment Market Forecast: Breakup by Treatment Type (USD Million), 2024-2032
4.    Global Neuroendocrine Tumours Treatment Historical Market: Breakup by Indication (USD Million), 2017-2023
5.    Global Neuroendocrine Tumours Treatment Market Forecast: Breakup by Indication (USD Million), 2024-2032
6.    Global Neuroendocrine Tumours Treatment Historical Market: Breakup by End Use (USD Million), 2017-2023
7.    Global Neuroendocrine Tumours Treatment Market Forecast: Breakup by End Use (USD Million), 2024-2032
8.    Global Neuroendocrine Tumours Treatment Historical Market: Breakup by Region (USD Million), 2017-2023
9.    Global Neuroendocrine Tumours Treatment Market Forecast: Breakup by Region (USD Million), 2024-2032
10.    North America Neuroendocrine Tumours Treatment Historical Market: Breakup by Country (USD Million), 2017-2023
11.    North America Neuroendocrine Tumours Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
12.    Europe Neuroendocrine Tumours Treatment Historical Market: Breakup by Country (USD Million), 2017-2023
13.    Europe Neuroendocrine Tumours Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
14.    Asia Pacific Neuroendocrine Tumours Treatment Historical Market: Breakup by Country (USD Million), 2017-2023
15.    Asia Pacific Neuroendocrine Tumours Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
16.    Latin America Neuroendocrine Tumours Treatment Historical Market: Breakup by Country (USD Million), 2017-2023
17.    Latin America Neuroendocrine Tumours Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
18.    Middle East and Africa Neuroendocrine Tumours Treatment Historical Market: Breakup by Country (USD Million), 2017-2023
19.    Middle East and Africa Neuroendocrine Tumours Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
20.    Global Neuroendocrine Tumours Treatment Market Structure

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER